Furthermore, data from phase I clinical trials of checkpoint inhibitors in childhood cancers shows that PD-L1 mRNA levels are a weak predictor of clinical response, even whilst most responders are PD-L1 positive by IHC [12, 13]. Here, CD274 is linked to childhood malignant neoplasm.